Skip to content

A clinical study on the alleviation of androgenetic alopecia symptoms by a cosmetic formulation containing inhibitors of PYGL, DP2, and 15-PGDH

A randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of Motiful Hair Tonic (tentative name) for the prevention of hair loss

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CRIS
Registry ID
KCT0010804
Enrollment
46
Registered
2025-07-24
Start date
2023-07-31
Completion date
Unknown
Last updated
2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Others(Cosmetics) : ?Motifull hair tonic, twice daily, 24 weeks, Spraying on scalp

Sponsors

P&K Skin Research Center
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1.Adults aged between 18 and 54 who have diagnosed with androgenetic alopecia 1-1) Adult patients diagnosed by Basic and specific (BASP) classification - basic type is a patient who is diagnosed with androgenetic alopecia with M1 or higher or C1 or higher or U1 or higher, - specific type is a patient who is diagnosed with androgenetic alopecia as V1 or higher or F1 or higher 1-2) Male patients diagnosed as 2 or 2A or higher by the Norwood-Hamilton classification 1-3) Female patients diagnosed as 1 or higher by the Ludwig classification 2.Subjects who will not have special hair care products or hair care and manipulation during the study period 3.Subjects who will maintain the same hair shape and color at the time of the first visit during the study period 4.Subjects who understand the purpose of this test and agrees in writing to the consent form

Exclusion criteria

Exclusion criteria: 1.Subjects who have severe acute kidney or heart disease or chronic diseases (hypertension, diabetes, etc.) that may affect the test results in the last 6 months 2.Females who are in the period of pregnant, breast-feeding or planning to be pregnant within 6 months 3.Subjects who have mental illness 4.Subjects who have infectious skin diseases 5.Subjects who have undergone surgical treatment for hair loss such as hair transplantation and scalp reduction 6.Subjects who have taken oral Dutasteride or Finasteride within the last 6 months 7.Subjects who have been applying topical hair growth, wool, and hair growth in the last 1 month 8.Subjects who are taking following medicines within 1 month: steroids, apoptotic drugs, vasodilator, antihypertensive drugs, anti-epileptics, beta-blockers, bronchodilator, diuretics, spironolactone, cimetidine, diazoxide, cyclosporine and ketoconazole 9.Subjects who have applied topical steroids to the scalp in the last 1 month 10.Subjects who are judged to have difficulty in applying test substances due to severe seborrheic dermatitis, scalp psoriasis, and scalp infection 11.Subjects who have other alopecia diseases such as alopecia areata, resting alopecia, and scarring alopecia, in addition to androgenetic alopecia 12.Subjects who are undernourished due to excessive dietary restrictions or stomach resection, or who take nutritional supplements that can affect hair loss 13.Any subjects who are considered to be inappropriate to participate in the study by the researcher

Design outcomes

Primary

MeasureTime frame
Hair density

Secondary

MeasureTime frame
?Visual Evaluation of Hair Density by Experts

Countries

Korea, Republic of

Contacts

Public ContactJin Hee Shin

P&K Skin Research Center

ppzini@hanmail.net+82-2-6925-1501

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026